NCT04802980View on ClinicalTrials.gov

A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor

PHASE1UnknownINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

April 28, 2020

Primary Completion Date

July 15, 2023

Study Completion Date

September 30, 2023

Conditions
Solid Tumor
Interventions
DRUG

HB002.1T

HB002.1T is a vascular endothelial growth factor receptor decoy

DRUG

Oxaliplatin

Oxaliplatin is an anti-tumor drug

DRUG

Capecitabine

Capecitabine is an anti-tumor drug

DRUG

Paclitaxel

Paclitaxel is an anti-tumor drug

DRUG

Gemcitabine

Gemcitabine is an anti-tumor drug

DRUG

Cisplatin

Cisplatin is an anti-tumor drug

DRUG

Carboplatin

Carboplatin is an anti-tumor drug

Trial Locations (1)

200123

RECRUITING

Shanghai East Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Huabo Biopharm Co., Ltd.

INDUSTRY